Actively Recruiting
Definitive Hypofractionated Intensity-modulated Radiation Theraphy With Concurrent Chemotherapy in Cervical Cancer
Led by Samsung Medical Center · Updated on 2026-02-27
34
Participants Needed
1
Research Sites
129 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to evaluate the efficacy and safety of hypofractionated intensity-modulated radiation therapy (IMRT) combined with concurrent chemotherapy in patients with cervical cancer. Conventional treatment usually requires 7-8 weeks, which increases the risk of toxicities and treatment delays. This trial seeks to shorten the overall treatment time while maintaining non-inferior tumor response and survival outcomes compared to standard therapy. The primary endpoint is tumor volume reduction rate (TVRR) assessed by pelvic MRI at 1 month after treatment. Secondary endpoints include 3-year local recurrence rate, progression-free survival, and incidence of acute and late grade ≥3 toxicities. The results of this study are expected to contribute to establishing an optimal treatment strategy for cervical cancer.
CONDITIONS
Official Title
Definitive Hypofractionated Intensity-modulated Radiation Theraphy With Concurrent Chemotherapy in Cervical Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed cervical cancer (squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma)
- FIGO stage IIB-IVA (2018)
- Measurable primary tumor on pelvic MRI within 30 days prior to treatment initiation
- Age 65 20 years
- ECOG performance status 0-1
- Adequate bone marrow function: WBC 65 3,000/bcL, ANC 65 1,000/bcL, platelets 65 100,000/bcL, hemoglobin 65 9 g/dL
- Adequate renal function: Creatinine < 2.0 mg/dL
- Ability to provide written informed consent
You will not qualify if you...
- Patients with distant metastasis
- Patients who have previously received pelvic radiotherapy
- Patients who have previously received definitive chemotherapy or chemoradiotherapy for diagnosed cervical cancer
- Patients who have undergone surgery for the current cervical cancer lesion
- Patients who underwent local excisional procedures of the cervix such as conization or Loop Electrosurgical Excision Procedure (LEEP) prior to radiotherapy
- Patients who are unable to undergo concurrent chemoradiotherapy due to poor general condition
- Patients with other active malignancies (except carcinoma in situ of the cervix, basal cell carcinoma of the skin, or superficial bladder cancer) within 3 years prior to enrollment or who experienced recurrence within 3 years after treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Samsung Medical Center
Seoul, Gangnam-gu, South Korea, 06351
Actively Recruiting
Research Team
W
won park
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here